A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
What is this summary about? Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesity. A study published in 2024 reported on the experiences of people taking semaglutide. People living…
Individuals who carry two copies of the apolipoprotein E ε4 (ε4) allele are at high risk of developing Alzheimer's disease (AD), yet the effects ofε4 homozygosity on biological pathways related to AD over the lifespan are unknown. Here we analyzed th…
OBJECTIVE: To evaluate two-year costs to insured patients treated with Roux-en-Y gastric bypass (RYGB) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes (T2D) and obesity. METHODS: Using the 2017 to 2023 Merative™ claims da…
Bimagrumab is an investigational antibody targeting type II activin receptors, intended to reduce total body and visceral fat mass and promote muscle growth. In this double-blind, placebo-controlled phase 2, trial, 507 adults with obesity (body mass…
OBJECTIVES: Diabetes mellitus, including new-onset diabetes after transplant, is a prevalent complication in solid-organ transplant recipients, often necessitating complex glycemic management. Glucagon-like peptide-1 receptor agonists, including sema…
Despite the cardiometabolic benefit of semaglutide, its impact on quality of life and whether patients' characteristics influence clinical outcomes and health-related quality of life (HRQoL) remain ambiguous.A retrospective review of patient charts w…
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity-management modalities e…
BACKGROUND: Non-invasive tests (NITs) are not currently approved as biomarkers of treatment response for patients with metabolic dysfunction-associated steatohepatitis (MASH). AIM: This retrospective study explored a panel of NITs for assessing respo…
AIMS: Atrial fibrillation (AF) is strongly associated with adverse outcomes, particularly in patients with heart failure (HF). AF susceptibility is driven by atrial remodelling, including electrical disarray, inflammation, and fibrosis, yet current t…
We present the case of a woman with heterozygous familial hypercholesterolemia with a history of myocardial infarction at 53 years of age. Her initial low-density lipoprotein (LDL) cholesterol level was 312 mg/dL, which was reduced to ~50 mg/dL using…
Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential r…
BACKGROUND: The gut microbiome is a critical regulator of host health, but how it mediates the therapeutic effects of drugs targeting neurodegenerative diseases like diabetic cognitive impairment (DCI) is unclear. Here, we investigated whether the ne…
BACKGROUND: Systemic inflammation contributes to the pathophysiology of heart failure (HF). Inflammation in heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) has been linked to card…
Glucagon-like peptide 1 (GLP-1) agonists continue to gain popularity in treating an increasing number of chronic conditions. As such, it is imperative that providers keep a vigilant eye on patients utilizing these medicines, monitoring for both known…
The prevalence of age-related dry eye disease (DED) is rapidly increasing with global aging, and progressive lacrimal gland (LG) dysfunction represents a central pathogenic mechanism for which targeted therapies remain limited. Semaglutide (Sema), a…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent worldwide, contributing to rising morbidity and mortality. In the United States, MASLD is among the most common chronic liver diseases, affecting an estimated…
PURPOSE OF REVIEW: This review aims to provide a comprehensive synthesis of current clinical evidence on the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dual glucose-depend…
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the management of obesity; however, respiratory complications are rarely documented. A 40-year-old person without diabetes with obesity (body mass index [BMI] 36 kg/m) developed ex…